[go: up one dir, main page]

MA45712B1 - Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations - Google Patents

Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations

Info

Publication number
MA45712B1
MA45712B1 MA45712A MA45712A MA45712B1 MA 45712 B1 MA45712 B1 MA 45712B1 MA 45712 A MA45712 A MA 45712A MA 45712 A MA45712 A MA 45712A MA 45712 B1 MA45712 B1 MA 45712B1
Authority
MA
Morocco
Prior art keywords
gprc5d
antibodies
antigen
binding fragments
antigen binding
Prior art date
Application number
MA45712A
Other languages
English (en)
Other versions
MA45712A (fr
Inventor
Alexey Teplyakov
Francois Gaudet
Ricardo Attar
Yingzhe Li
Leopoldo LUISTRO
Diana CHIN
Suzanne EDAVETTAL
Nathan MAJEWSKI
Mark MENDONCA
Kondandaram PILLARISETTI
Mark Tornetta
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of MA45712A publication Critical patent/MA45712A/fr
Publication of MA45712B1 publication Critical patent/MA45712B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps qui se lient spécifiquement à GPRC5D. L'invention concerne également des polynucléotides associés susceptibles de coder pour les anticorps spécifiques à GPRC5D de l'invention ou des fragments de liaison à l'antigène, des cellules exprimant les anticorps de l'invention ou les fragments de liaison, ainsi que des vecteurs associés et des fragments de liaison à l'antigène ou des anticorps marqués de manière détectable. L'invention concerne en outre des procédés d'utilisation de ces anticorps. Par exemple, les anticorps de l'invention peuvent être utilisés pour diagnostiquer, traiter ou surveiller la progression, la régression ou la stabilité d'un cancer exprimant GPRC5D ; pour déterminer si un patient doit être traité contre le cancer ; ou pour déterminer si un sujet est atteint d'un cancer exprimant GPRC5D et, par conséquent, peut être sensible au traitement avec un agent thérapeutique anticancéreux spécifique à GPRC5D, tel que les anticorps multispécifiques contre GPRC5D et CD3 selon l'invention.
MA45712A 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations MA45712B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364811P 2016-07-20 2016-07-20
PCT/US2017/042982 WO2018017786A2 (fr) 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
EP17745951.8A EP3487882B1 (fr) 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA45712A MA45712A (fr) 2019-05-29
MA45712B1 true MA45712B1 (fr) 2025-09-30

Family

ID=60992891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45712A MA45712B1 (fr) 2016-07-20 2017-07-20 Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations

Country Status (38)

Country Link
US (4) US10562968B2 (fr)
EP (2) EP3487882B1 (fr)
JP (3) JP7292200B2 (fr)
KR (3) KR20250073578A (fr)
CN (2) CN109715667B (fr)
AR (4) AR109499A1 (fr)
AU (2) AU2017299673B2 (fr)
BR (1) BR112019001055A2 (fr)
CA (1) CA3031472A1 (fr)
CL (4) CL2019000146A1 (fr)
CO (1) CO2019001114A2 (fr)
CR (1) CR20190025A (fr)
DK (1) DK3487882T3 (fr)
EA (1) EA201990346A1 (fr)
EC (1) ECSP19012075A (fr)
ES (1) ES3042078T3 (fr)
FI (2) FI3487882T3 (fr)
HR (1) HRP20251181T1 (fr)
HU (1) HUE073077T2 (fr)
IL (2) IL298277A (fr)
IN (1) IN201917002488A (fr)
LT (2) LT3487882T (fr)
MA (1) MA45712B1 (fr)
MX (3) MX2019000825A (fr)
NI (1) NI201900005A (fr)
NZ (2) NZ790480A (fr)
PE (2) PE20190392A1 (fr)
PH (1) PH12019500152A1 (fr)
PL (1) PL3487882T3 (fr)
PT (1) PT3487882T (fr)
RS (1) RS67235B1 (fr)
SG (1) SG11201900468YA (fr)
SI (1) SI3487882T1 (fr)
SM (1) SMT202500356T1 (fr)
TW (1) TWI781108B (fr)
UY (5) UY40768A (fr)
WO (1) WO2018017786A2 (fr)
ZA (1) ZA201901066B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2018035710A1 (fr) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
TW201837174A (zh) * 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
KR20220080044A (ko) * 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
CN111116753A (zh) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
KR20210099614A (ko) * 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
TWI861039B (zh) * 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
EP3911677A1 (fr) * 2019-01-18 2021-11-24 Janssen Biotech, Inc. Récepteurs antigéniques chimériques gprc5d et cellules les exprimant
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
EP3994270A1 (fr) 2019-07-02 2022-05-11 Fred Hutchinson Cancer Research Center Vecteurs ad35 recombinants et améliorations de thérapie génique associées
JP2022543553A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
WO2021018925A1 (fr) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Anticorps se liant à gprc5d
KR20220122656A (ko) * 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
JP7285495B2 (ja) * 2020-03-30 2023-06-02 国立大学法人三重大学 二重特異的抗体
CA3189562A1 (fr) * 2020-07-17 2022-01-20 Janssen Biotech, Inc. Anticorps anti-idiotypiques diriges contre des anticorps anti-gprc5d
CA3194796A1 (fr) 2020-09-16 2022-03-24 Janssen Biotech, Inc. Methodes de traitement d'un myelome multiple
CN116574184A (zh) * 2021-01-05 2023-08-11 上海礼新医药研发有限公司 抗gprc5d单克隆抗体及其用途
WO2022148370A1 (fr) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anticorps monoclonaux anti-gprc5d et leurs utilisations
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
JP2024510098A (ja) * 2021-02-19 2024-03-06 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用
US12103977B2 (en) 2021-03-24 2024-10-01 Janssen Biotech, Inc. Trispecific antibody targeting CD79b, CD20, and CD3
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
WO2022247804A1 (fr) * 2021-05-23 2022-12-01 上海祥耀生物科技有限责任公司 Anticorps anti-gprc5d, son procédé de préparation et son utilisation
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
WO2023078382A1 (fr) 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 Anticorps se liant à gprc5d et son utilisation
WO2023173272A1 (fr) * 2022-03-15 2023-09-21 上海驯鹿生物技术有限公司 Récepteur antigénique chimérique (car) entièrement humanisé ciblant gprc5d et son utilisation
KR20240125026A (ko) * 2021-12-21 2024-08-19 상하이 이아소 바이오테크놀로지 씨오., 엘티디. Gprc5d를 표적으로 하는 완전 인간 항체와 키메라 항원 수용체(car) 및 이의 용도
WO2023115347A1 (fr) * 2021-12-21 2023-06-29 上海驯鹿生物技术有限公司 Anticorps entièrement humain ciblant gprc5d
CN116375867A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 抗gprc5d抗体及其应用
WO2023125888A1 (fr) * 2021-12-31 2023-07-06 山东先声生物制药有限公司 Anticorps gprc5d et son utilisation
WO2023125729A1 (fr) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 Anticorps humanisé anti-cd3 et son utilisation dans la préparation d'un anticorps bispécifique
US20250092135A1 (en) 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
JP2025508343A (ja) * 2022-01-29 2025-03-26 ▲かい▼興生命科技（上海）有限公司 Ｇｐｒｃ５ｄ抗体及びその使用
MX2024011128A (es) * 2022-03-14 2024-09-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
CA3247475A1 (fr) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions et méthodes permettant la destruction de cellule tumorale universelle
AU2023275810A1 (en) * 2022-05-27 2024-12-12 Antengene Biologics Limited Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2023236889A1 (fr) * 2022-06-06 2023-12-14 山东先声生物制药有限公司 Anticorps multi-spécifique ciblant bcma, gprc5d et lymphocytes t et son application
WO2024002308A1 (fr) 2022-06-30 2024-01-04 康诺亚生物医药科技（成都）有限公司 Développement et utilisation d'un nouvel inhibiteur de tumeur multispécifique
WO2024017326A1 (fr) * 2022-07-21 2024-01-25 山东先声生物制药有限公司 Nanocorps anti-gprc5d et son utilisation
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
CN116003598B (zh) 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 靶向人gprc5d的重组人源化单克隆抗体及其应用
AU2023334858A1 (en) 2022-09-01 2025-03-20 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
KR20250057914A (ko) * 2022-09-09 2025-04-29 베이징 맵웍스 바이오테크 컴퍼니 리미티드 다중-특이적 항체 결합 bcma, gprc5d 및 cd3 및 이의 용도
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
WO2024102954A1 (fr) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Système d'écrêtage induit par activation (aics)
KR20250123204A (ko) * 2022-12-22 2025-08-14 얀센 파마슈티카 엔브이 항체-폴리뉴클레오티드 접합체의 제조 방법
TW202434644A (zh) 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
US20240392027A1 (en) 2023-02-28 2024-11-28 Janssen Biotech Inc. Compositions comprising a bispecific gprc5d/cd3 antibody
CN120882747A (zh) * 2023-03-22 2025-10-31 百放英库医药科技(北京)有限公司 一种抗gprc5d纳米抗体及其应用
AU2024260168A1 (en) * 2023-04-28 2025-12-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody targeting g protein-coupled receptor
TW202446793A (zh) * 2023-05-16 2024-12-01 大陸商上海齊魯製藥研究中心有限公司 雙特異性抗原結合分子及其應用
WO2024246856A1 (fr) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple
AU2024283895A1 (en) 2023-06-06 2025-12-18 Fortvita Biologics Inc. Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
CN120129703A (zh) * 2023-06-09 2025-06-10 德琪(杭州)生物有限公司 靶向cd3和另一靶点的新颖抗体及其用途
TW202500590A (zh) * 2023-06-28 2025-01-01 大陸商浙江博銳生物製藥有限公司 抗ｇｐｒｃ５ｄ抗體及其醫藥用途
WO2025019733A2 (fr) * 2023-07-20 2025-01-23 Janssen Biotech, Inc. Procédés de traitement du myélome multiple
WO2025059362A1 (fr) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
WO2025056013A1 (fr) * 2023-09-13 2025-03-20 江苏恒瑞医药股份有限公司 Composition pharmaceutique comprenant un anticorps bispécifique se liant de manière spécifique à gprc5d et cd3
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025076472A1 (fr) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
WO2025094085A1 (fr) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Schémas combinés pour le traitement du myélome multiple
US20250188163A1 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Gprc5d antibodies with enhanced effector function and uses thereof
WO2025134049A1 (fr) 2023-12-21 2025-06-26 Janssen Biotech, Inc Anticorps trispécifique ciblant bcma, gprc5d et cd3 pour le traitement de l'amylose al
WO2025134050A1 (fr) 2023-12-21 2025-06-26 Janssen Biotech, Inc Anticorps trispécifique ciblant bcma, gprc5d et cd3 pour le traitement du myélome multiple
WO2025147545A1 (fr) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et procédés et utilisations associés
CN117843788B (zh) * 2024-01-09 2025-02-11 四川大学 一种抗gprc5d的抗体及其多特异性抗体和相关应用
CN118108846B (zh) * 2024-02-04 2024-11-26 四川大学华西医院 靶向GPRC5D同种异体CAR-γδT细胞的制备及应用
WO2025194478A1 (fr) * 2024-03-22 2025-09-25 Biofront Ltd Anticorps se liant à cd3 et gprc5d et leurs utilisations
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025259877A1 (fr) * 2024-06-12 2025-12-18 Evolveimmune Therapeutics, Inc. Molécules de fusion d'anticorps bispécifique ciblant gprc5d et cd3 et leurs procédés d'utilisation
WO2026001931A1 (fr) * 2024-06-24 2026-01-02 南京蓬勃生物科技有限公司 Molécule se liant à gprc5d et son utilisation
US20260014252A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1468694A1 (fr) 2001-12-27 2004-10-20 Sumitomo Pharmaceuticals Company, Limited Medicaments contre l'anorexie ou des affections liees au mode de vie et procede de recherche systematique de ces medicaments
WO2005086568A2 (fr) 2004-01-26 2005-09-22 Morphosys Ag Anticorps anti-icam 1 humains et utilisations de ceux-ci
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1940881B1 (fr) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
EP2155788B1 (fr) 2007-04-03 2012-06-27 Micromet AG Éléments de liaison bispécifiques spécifiques d'espèces croisées
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
RS58217B1 (sr) 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
CN102099378B (zh) * 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
PL2352763T5 (pl) 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
DK2356153T3 (en) 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
EP2352765B1 (fr) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Anticorps monocaténaire bispécifique à domaine unique, spécifique d'espèces croisées
EP3128048B1 (fr) 2008-10-31 2018-11-28 Janssen Biotech, Inc. Compositions supports à base du domaine de la fibronectine de type iii, procédés et utilisations
RU2562700C2 (ru) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
FR2994803B1 (fr) 2012-08-30 2016-02-26 Oreal Modulation de la forme des fibres keratiniques
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
CA2959171C (fr) 2014-09-05 2023-11-14 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
KR20230159637A (ko) * 2014-12-05 2023-11-21 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
WO2016209921A1 (fr) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
EA201890513A1 (ru) 2015-08-17 2018-11-30 Янссен Фармацевтика Нв Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение
KR20180072820A (ko) 2015-11-02 2018-06-29 얀센 파마슈티카 엔.브이. 항-il1rap 항체, il1rap 및 cd3과 결합하는 이중특이성 항원 결합 분자, 및 그의 용도
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
US11970542B2 (en) 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies
CA3194796A1 (fr) 2020-09-16 2022-03-24 Janssen Biotech, Inc. Methodes de traitement d'un myelome multiple
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物

Also Published As

Publication number Publication date
AR133827A2 (es) 2025-11-05
CL2019000146A1 (es) 2019-04-26
LTPA2026501I1 (fr) 2026-01-26
CN109715667A (zh) 2019-05-03
UY40768A (es) 2024-06-28
TW201809005A (zh) 2018-03-16
IL264334B2 (en) 2024-05-01
KR20230128409A (ko) 2023-09-04
SG11201900468YA (en) 2019-02-27
CN109715667B (zh) 2022-12-30
AR133826A2 (es) 2025-11-05
CO2019001114A2 (es) 2019-02-19
US11884722B2 (en) 2024-01-30
EP3487882A2 (fr) 2019-05-29
CL2024001016A1 (es) 2024-10-04
HRP20251181T1 (hr) 2025-12-05
TWI781108B (zh) 2022-10-21
HUE073077T2 (hu) 2025-12-28
KR20250073578A (ko) 2025-05-27
JP2023011774A (ja) 2023-01-24
CL2024001015A1 (es) 2024-10-04
CR20190025A (es) 2019-03-14
MX2019000825A (es) 2019-09-04
LT3487882T (lt) 2025-10-10
AU2017299673A1 (en) 2019-02-07
JP7292200B2 (ja) 2023-06-16
US10562968B2 (en) 2020-02-18
NZ790480A (en) 2025-12-19
RS67235B1 (sr) 2025-10-31
AU2024205021A1 (en) 2024-08-15
CL2024000444A1 (es) 2024-08-23
US11685777B2 (en) 2023-06-27
PE20190392A1 (es) 2019-03-13
IL264334A (en) 2019-02-28
CA3031472A1 (fr) 2018-01-25
EP4643953A2 (fr) 2025-11-05
UY40769A (es) 2024-06-28
PH12019500152A1 (en) 2019-10-14
AR109499A1 (es) 2018-12-19
ES3042078T3 (en) 2025-11-18
KR102811945B1 (ko) 2025-05-23
KR20190028534A (ko) 2019-03-18
EA201990346A1 (ru) 2019-06-28
JP7469432B2 (ja) 2024-04-16
IL298277A (en) 2023-01-01
CN116333133A (zh) 2023-06-27
ZA201901066B (en) 2020-10-28
FI3487882T3 (fi) 2025-09-25
AR132097A2 (es) 2025-05-28
PE20240884A1 (es) 2024-04-24
UY40770A (es) 2024-06-28
SI3487882T1 (sl) 2025-11-28
NI201900005A (es) 2019-05-10
BR112019001055A2 (pt) 2019-10-01
SMT202500356T1 (it) 2025-11-10
MX2023006449A (es) 2023-06-15
PT3487882T (pt) 2025-10-13
WO2018017786A3 (fr) 2018-03-01
ECSP19012075A (es) 2019-02-28
JP2019527061A (ja) 2019-09-26
MA45712A (fr) 2019-05-29
JP2024054176A (ja) 2024-04-16
IN201917002488A (fr) 2019-04-26
WO2018017786A2 (fr) 2018-01-25
US20180037651A1 (en) 2018-02-08
UY40672A (es) 2024-04-30
US20240343796A1 (en) 2024-10-17
MX2024001615A (es) 2024-02-28
IL264334B1 (en) 2024-01-01
UY37340A (es) 2018-01-31
FIC20265003I1 (fi) 2026-01-12
EP3487882B1 (fr) 2025-07-16
PL3487882T3 (pl) 2025-11-17
KR102572091B1 (ko) 2023-08-31
DK3487882T3 (da) 2025-09-22
NZ750152A (en) 2025-12-19
AU2017299673B2 (en) 2024-08-01
US20230227548A1 (en) 2023-07-20
US20230084967A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
PH12019500152A1 (en) Anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
PH12018500938A1 (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind ili1rap and cd3, and uses thereof
MX2022006650A (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos.
PH12017500472A1 (en) Cd123 binding agents and uses thereof
PH12019502274A1 (en) Antibodies binding to steap-1